Docetaxel News and Research

RSS

Docetaxel is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of breast and non-small cell lung cancer (NSCLC). It is also approved to be used with other drugs to treat squamous cell carcinoma of the head and neck (SCCHN) and certain types of gastric and prostate cancer.

Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent.

Global study shows long-term survival benefit for a subset of patients with advanced lung cancer

According to the results of a large, global study led by Yale Cancer Center researchers, even a tiny amount of a biomarker known as PD-L1 (programmed death-ligand1) can predict a long-term survival benefit from using pembrolizumab (Keytruda).

20 Feb 2020

Novel inhibitor to fight metastatic prostate cancer shows promise

When prostate cancer spreads it is often a deadly disease, but now a Stony Brook University-led research team believes a new approach that inhibits a specific fatty acid binding protein (FABP) may be the key to halting disease progression.

30 Jan 2020

Magnetic nanomaterials may become the basis for new approach to treating liver fibrosis

A team of scientists from Immanuel Kant Baltic Federal University together with their colleagues from NUST MISiS and RWTH Aachen University (Germany) compared different treatments against liver fibrosis and published the results of their study in the Cells journal.

21 Jan 2020

New drug combo promises help for triple negative breast cancer patients

A new preclinical study on triple negative breast cancer (TNBC) reports that an experimental polo-like kinase 1 (PLK1) inhibitor shrank tumor four times more powerfully when used along with standard drugs than alone. The study, reported in the journal PLOS ONE, opens up a new door of opportunity for patients with this disease.

11 Dec 2019

Combination regimen shows promising results in preclinical models of triple negative breast cancer

Tumor volume in a preclinical model of triple negative breast cancer (TNBC) was reduced four times more when an experimental polo-like kinase 1 (PLK1) inhibitor was combined with a standard-of-care chemotherapeutic agent than when the agent was used alone.

10 Dec 2019

Prostate cancer 'super responders' could live for two years or more on immunotherapy

Some men with advanced prostate cancer who have exhausted all other treatment options could live for two years or more on immunotherapy, a major clinical trial has shown.

27 Nov 2019

Biosimilar for HER2+ breast cancer achieves similar overall response rate to reference drug

The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously untreated metastatic breast cancer, according to a large, randomized phase III study reported at the ESMO Asia 2019 Congress.

22 Nov 2019

Improving the efficiency of antiangiogenic and antifibrotic drug for treatment of lung cancer

The University of Barcelona and Hospital Clínic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic and antifibrotic drug, for the treatment of lung cancer.

19 Nov 2019

Modern chemo more effective than second targeted hormone therapy against resistant prostate cancer

A modern chemotherapy drug is more effective for men with advanced prostate cancer than a second targeted hormone therapy in patients who have stopped responding to treatment, a major clinical trial shows.

30 Sep 2019

Study links high number of copies of chromosomal region to chemotherapeutic drug resistance

Researchers at the Bellvitge Biomedical Research Institute, with the participation of collaborators from the Baylor College of Medicine and the University Institute of Oncology of Asturias, publish today in Cancer Research a study where they relate the high number of copies of a chromosomal region with the appearance of resistance to a chemotherapeutic drug.

19 Jun 2019

Oral androgen receptor inhibitor improves outcomes for men with mHSPC

Enzalutamide, an oral androgen receptor inhibitor, can improve outcomes for men with metastatic hormone-sensitive prostate cancer, according to a large study presented by Christopher Sweeney, MBBS of Dana-Farber Cancer Institute's Lank Center for Genitourinary Oncology, during the American Society of Clinical Oncology Annual Meeting.

3 Jun 2019

Monoclonal antibody pembrolizumab prolongs survival in patients with squamous cell carcinoma

Squamous cell carcinoma is one of the most common cancers of the skin and mucosa. Treatment options for the advanced stage have been very limited for patients with tumors of the head and neck, i.e. in the mouth, the pharynx or the larynx: If recurrences or metastases occur during or after platinum-based chemotherapy, the disease is generally considered incurable.

18 Jan 2019

Study defines biomarker in response to treatment of castration-resistant prostate cancer

The most aggressive type of prostate cancer, castration-resistant prostate cancer, can be treated with two different therapies: taxanes or hormone treatment. Until this day there are no comparative studies between the two and the decision on which treatment to use is done empirically and based on the patient's preferences.

14 Nov 2018

Prostate radiotherapy improves survival in men with low burden of metastatic disease

Radiotherapy to the prostate improves overall survival in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden but not in those with higher burden of disease, according to results from a pre-planned analysis of a large comparison study reported at ESMO 2018.

22 Oct 2018

Researchers discover secret communication hotline between breast cancers and normal cells

Australian researchers have uncovered a secret communication hotline between breast cancers and the normal cells surrounding them. Importantly, the messages sent back and forth between the normal and tumour cells encourage the cancer to survive and to become more aggressive.

13 Aug 2018

New combination therapy for cancer cells could soon be a reality

A new cancer therapy using nanoparticles to deliver a combination therapy direct to cancer cells could be on the horizon, thanks to research from the University of East Anglia.

From Precision NanoSystems Inc. 10 Aug 2018

European Commission approves Pfizer’s first oncology biosimilar

Pfizer Inc. today announced the European Commission has approved TRAZIMERA, a biosimilar to Herceptin (trastuzumab), for the treatment of human epidermal growth factor overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

31 Jul 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018